Skip to main content
TC

Translational Cures

Translational Cures is a digital contract research organization that utilizes human organ-on-a-chip technology and AI-driven computational modeling to evaluate the safety and efficacy of drugs for rare diseases. By providing alternatives to traditional animal testing, the company accelerates the development of new therapies without the need for large clinical trials.

Silver Spring, United StatesFounded 2024310+ followers
Updated 3 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Traditional drug development for rare diseases faces significant hurdles due to the limited availability of patients for clinical trials and the ethical concerns surrounding extensive animal testing. The high cost and lengthy timelines associated with these traditional methods often delay or prevent the development of effective treatments for these conditions.

Solution

Translational Cures is a contract research organization (CRO) that accelerates drug development by applying novel technologies to the FDA-regulated phases. The company leverages AI-driven computational modeling, human organ-on-a-chip technology, and Bayesian evidence of effectiveness to evaluate drug safety and efficacy. By providing alternatives to traditional animal testing and large randomized clinical trials, Translational Cures enables the development of therapies for rare diseases and emergency care scenarios where traditional trials are not feasible. Their approach aims to reduce the time and cost associated with bringing new cures to patients.

Target Audience

Translational Cures primarily targets pharmaceutical companies, research institutions, and other organizations involved in drug development, particularly those focused on rare diseases and areas with unmet medical needs.

Features

  • AI-driven computational modeling for predicting drug efficacy and safety
  • Human organ-on-a-chip technology for in vitro clinical trials
  • Application of Bayesian evidence of effectiveness to support regulatory submissions
  • Focus on innovating in the FDA-regulated phases of drug development
  • Expertise in regulatory science to address drug development challenges
This profile is AI-generated and may contain inaccuracies.